丙肝治疗起始对伴随用药依从性的影响。
Impact of hepatitis C treatment initiation on adherence to concomitant medications.
出版信息
J Assoc Nurses AIDS Care. 2014 Jan-Feb;25(1):23-31. doi: 10.1016/j.jana.2013.07.004. Epub 2013 Sep 24.
Our study investigated whether initiating hepatitis C virus (HCV) treatment affected adherence to concomitant medications. Mixed-effects linear regression was used to analyze data from 57 patients (29 co-infected with HIV) in a prospective study of HCV treatment-naïve patients initiating HCV treatment. Adherence was assessed using structured self-report at the time of treatment initiation, and at 12 weeks and 24 weeks into treatment. There was no change in adherence to concomitant medications over the first 24 weeks of HCV treatment. There was a significant interaction effect such that the change in adherence to concomitant medications between baseline and 12 weeks differed between the HIV-infected and HIV-uninfected patients. Adherence to concomitant medications in the HIV-infected patients was found to decrease, whereas adherence in the HIV-uninfected patients was found to increase. HIV-infected patients may be more at risk for adherence problems in the first 12 weeks of HCV treatment as compared to HIV-uninfected patients.
我们的研究调查了启动丙型肝炎病毒 (HCV) 治疗是否会影响伴随药物的依从性。我们使用混合效应线性回归分析了一项前瞻性 HCV 初治患者 HCV 治疗开始研究中 57 名患者（29 名合并感染 HIV）的数据。在治疗开始时、治疗 12 周和 24 周时通过结构化自我报告评估依从性。在 HCV 治疗的前 24 周内，伴随药物的依从性没有变化。存在显著的交互效应，即 HIV 感染和未感染患者在基线和 12 周时伴随药物依从性的变化不同。发现 HIV 感染患者的伴随药物依从性下降，而 HIV 未感染患者的伴随药物依从性增加。与 HIV 未感染患者相比，HIV 感染患者在 HCV 治疗的前 12 周可能更易出现依从性问题。
Zotero 插件